Advertisement

Tumor Biology

, Volume 36, Issue 8, pp 5849–5857 | Cite as

PTEN gene is infrequently hypermethylated in human esophageal squamous cell carcinoma

Research Article

Abstract

Whether promoter hypermethylation of phosphatase and tensin homologue deleted from chromosome 10 (PTEN) is associated with loss of PTEN expression was not yet elucidated in esophageal squamous cell carcinoma (ESCC). The methylation status of PTEN gene was evaluated in 74 ESCC specimens and four esophageal cancer cell lines. Its association with clinicopathological factors or the prognosis was investigated by statistical analysis. We further measured messenger RNA (mRNA) and protein level of PTEN by quantitative RT-PCR and immunohistochemistry and studied the role of PTEN hypermethylation in loss of PTEN expression in clinical samples. Next, demethylation of PTEN gene with 5-azaC in EC9706 was performed to confirm the clinical findings. PTEN methylation was only found in 14 (18.9 %) of 74 ESCC tumor samples and one (EC9706) of four esophageal cancer cell lines. PTEN methylation was not statistically associated with clinicopathological factors and the prognosis (p > 0.05). In addition, 41 patients (55.4 %) and 38 patients (51.4 %) showed reduced mRNA level of PTEN and negative expression of PTEN protein in ESCC tumors, respectively. Detailed analysis indicated that PTEN methylation was a possible mechanism of loss of PTEN expression in ESCC, and further 5-azaC demethylation revealed inversed methylation status and increased mRNA or protein level of PTEN in EC9706. However, the role of PTEN methylation in loss of PTEN expression was still limited due to low frequency of methylation in ESCC. PTEN hypermethylation is a rare event and did not play an important role in the prognosis and loss of PTEN expression in ESCC.

Keywords

ESCC PTEN hypermethylation Loss of PTEN expression Prognosis 

Notes

Acknowledgments

The authors thank the Department of Pathology, Provincial Hospital Affiliated to Shandong University, for specimen collections and staining evaluation. This work was supported by the National Natural Science Foundation of China (No. 81172161), Shandong Provincial Science and Technology Development Plan (2012GSF11816), and Jinan Science and Technology Plan (201202041).

References

  1. 1.
    Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem. 1998;273:13375–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci. 2012;125:4687–92.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kondo Y, Hollingsworth EF, Kondo S. Molecular targeting for malignant gliomas. Int J Oncol. 2004;24:1101–9.PubMedGoogle Scholar
  4. 4.
    Koksal IT, Dirice E, Yasar D, Sanlioglu AD, Ciftcioglu A, Gulkesen KH, et al. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol. 2004;22:307–12.CrossRefPubMedGoogle Scholar
  5. 5.
    Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer. 2003;10:203–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer. 2006;51:181–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Im SA, Lee KE, Nam E, Kim DY, Lee JH, Han HS, et al. Potential prognostic significance of p185 (HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori. 2005;91:513–21.PubMedGoogle Scholar
  8. 8.
    Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22:183–98.CrossRefPubMedGoogle Scholar
  9. 9.
    Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002;8:1178–84.PubMedGoogle Scholar
  10. 10.
    Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006;66:6546–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol. 2007;9:271–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
  13. 13.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.CrossRefPubMedGoogle Scholar
  16. 16.
    Lee PC, Port JL, Paul S, Stiles BM, Altorki NK. Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases. Ann Thorac Surg. 2009;88:186–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Selaru FM, David S, Meltzer SJ, Hamilton JP. Epigenetic events in gastrointestinal cancer. Am J Gastroenterol. 2009;104:1910–2.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Pan QF, Li WT, Dong HC, Chen YZ, Yin L, Liu W, et al. PTEN hypermethylation profiles of Chinese Kazakh patients with esophageal squamous cell carcinoma. Dis Esophagus. 2014;27:396–402.CrossRefPubMedGoogle Scholar
  20. 20.
    Kim DS, Lee SM, Yoon GS, Choi JE, Park JY. Infrequent hypermethylation of the PTEN gene in Korean non-small-cell lung cancers. Cancer Sci. 2010;101:568–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Chang D, Wang TY, Li HC, Wei JC, Song JX. Prognostic significance of PTEN expression in esophageal squamous cell carcinoma from Linzhou City, a high incidence area of northern China. Dis Esophagus. 2007;20:491–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J Cell Sci. 2008;121:249–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–62.CrossRefPubMedGoogle Scholar
  24. 24.
    Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene. 1998;16:1743–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res. 1997;57:5254–7.PubMedGoogle Scholar
  26. 26.
    Hu YC, Lam KY, Tang JC, Srivastava G. Mutational analysis of the PTEN/MMAC1 gene in primary oesophageal squamous cell carcinomas. Mol Pathol. 1999;52:353–6.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Chang JG, Chen YJ, Perng LI, Wang NM, Kao MC, Yang TY, et al. Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract. Eur J Cancer. 1999;35:647–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Investig. 2002;82:285–91.CrossRefPubMedGoogle Scholar
  29. 29.
    Tachibana M, Shibakita M, Ohno S, Kinugasa S, Yoshimura H, Ueda S, et al. Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer. 2002;94:1955–60.CrossRefPubMedGoogle Scholar
  30. 30.
    Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, Stivala F, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia. 2011;25:1064–79.CrossRefPubMedGoogle Scholar
  31. 31.
    Whelan JT, Forbes SL, Bertrand FE. CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle. 2007;6:80–4.CrossRefPubMedGoogle Scholar
  32. 32.
    Bar N, Dikstein R. miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS ONE. 2010;5:e10859.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, et al. The PTEN regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 2009;23:1327–37.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Thoracic SurgeryProvincial Hospital Affiliated to Shandong UniversityJinanChina
  2. 2.Faculty of Health SciencesSouthampton UniversitySouthamptonUK

Personalised recommendations